MA27728A1 - Antagonistes des recepteurs de cgrp - Google Patents

Antagonistes des recepteurs de cgrp

Info

Publication number
MA27728A1
MA27728A1 MA28550A MA28550A MA27728A1 MA 27728 A1 MA27728 A1 MA 27728A1 MA 28550 A MA28550 A MA 28550A MA 28550 A MA28550 A MA 28550A MA 27728 A1 MA27728 A1 MA 27728A1
Authority
MA
Morocco
Prior art keywords
cgrp
antagonists
compounds
cgrp receptors
involved
Prior art date
Application number
MA28550A
Other languages
English (en)
Inventor
Christopher S Burgey
Zhengwu J Deng
Diem N Nguyen
Daniel V Paone
Anthony W Shaw
Theresa M Williams
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA27728A1 publication Critical patent/MA27728A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EXTRAIT La présente invention vise les composés de la Formule (I): (oé les variables R1, R2 et R3 sont telles que définies dans ces présentes) utiles comme antagonistes des récepteurs de CGRP et utiles pour le traitement ou la prévention des maladies dans lesquelles le CGRP est impliqué, comme le mal de tête, la migraine ou le névralgisme facial. L'invention vise également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de ces maladies dans lesquelles le CGRP est impliqué.
MA28550A 2003-04-15 2005-10-11 Antagonistes des recepteurs de cgrp MA27728A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
MA27728A1 true MA27728A1 (fr) 2006-01-02

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28550A MA27728A1 (fr) 2003-04-15 2005-10-11 Antagonistes des recepteurs de cgrp

Country Status (32)

Country Link
US (6) US6953790B2 (fr)
EP (2) EP2039694B1 (fr)
JP (1) JP3967766B2 (fr)
KR (1) KR100769030B1 (fr)
CN (1) CN100384843C (fr)
AR (1) AR045887A1 (fr)
AT (1) ATE413400T1 (fr)
AU (1) AU2004230926B2 (fr)
BR (1) BRPI0409601A (fr)
CA (1) CA2522220C (fr)
CL (1) CL2004000788A1 (fr)
CO (1) CO5640130A2 (fr)
CY (1) CY1108714T1 (fr)
DE (1) DE602004017608D1 (fr)
DK (1) DK1638969T3 (fr)
EC (1) ECSP056097A (fr)
ES (1) ES2314417T3 (fr)
HR (1) HRP20080666T3 (fr)
IS (1) IS2759B (fr)
JO (1) JO2355B1 (fr)
MA (1) MA27728A1 (fr)
MX (1) MXPA05011166A (fr)
NO (1) NO327655B1 (fr)
NZ (1) NZ543357A (fr)
PE (1) PE20050020A1 (fr)
PL (1) PL1638969T3 (fr)
PT (1) PT1638969E (fr)
RU (1) RU2308458C2 (fr)
SI (1) SI1638969T1 (fr)
TW (1) TWI314931B (fr)
UA (1) UA82877C2 (fr)
WO (2) WO2004092168A1 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
RS52552B (sr) * 2002-06-05 2013-04-30 Bristol-Myers Squibb Company Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom
ATE466860T1 (de) * 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
CA2529227A1 (fr) * 2003-06-26 2005-01-06 Merck & Co., Inc. Antagonistes du recepteur cgrp de benzodiazepine
EP1641423B1 (fr) * 2003-06-26 2010-03-17 Merck Sharp & Dohme Corp. Benzodiazepines antagonistes du recepteur cgrp
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
CN101124217A (zh) * 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
WO2005082849A1 (fr) * 2004-02-23 2005-09-09 Trustees Of Tufts College Lactames utilisees comme inhibiteurs peptidomimetiques a contrainte conformationnelle
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7659264B2 (en) * 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2006044449A2 (fr) * 2004-10-14 2006-04-27 Merck & Co., Inc. Antagonistes des recepteurs du cgrp (peptide lie au gene de la calcitonine)
DE602005027230D1 (de) 2004-10-22 2011-05-12 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2423085C (en) * 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
CA2599925A1 (fr) 2005-03-14 2006-09-21 Merck & Co., Inc. Antagonistes du recepteur du cgrp
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP3069731A1 (fr) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistes d'anticorps dirigés contre un peptide associé au gène de la calcitonine et procédés les utilisant
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
WO2007061677A2 (fr) * 2005-11-18 2007-05-31 Merck & Co., Inc. Antagoniste du recepteur cgpr de spirolactam aryle
CN101421266A (zh) 2006-04-10 2009-04-29 默克公司 制备cgrp拮抗剂的方法
JP2009533438A (ja) * 2006-04-10 2009-09-17 メルク エンド カムパニー インコーポレーテッド ピリジン複素環ｃｇｒｐアンタゴニスト中間体の製造方法
US7718796B2 (en) 2006-04-10 2010-05-18 Merck Sharp & Dohme Corp. Process for the preparation of caprolactam CGRP antagonist
WO2007120592A1 (fr) * 2006-04-10 2007-10-25 Merck & Co., Inc. Sel antagoniste de cgrp
ATE517903T1 (de) 2006-05-02 2011-08-15 Bristol Myers Squibb Co Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
US7470680B2 (en) 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
AU2007284994B2 (en) * 2006-05-09 2010-04-22 Merck Sharp & Dohme Corp. Substituted spirocyclic CGRP receptor antagonists
EP2027106A2 (fr) * 2006-06-13 2009-02-25 Vertex Pharmaceuticals Incorporated Antagonistes du récepteur du cgrp
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US7834000B2 (en) * 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
PL2069352T3 (pl) * 2006-08-02 2014-03-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby
WO2008030524A2 (fr) * 2006-09-08 2008-03-13 Merck & Co., Inc. Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp
NZ580887A (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
CA2722536A1 (fr) * 2008-02-05 2009-08-13 Merck & Co., Inc. Promedicaments d'antagoniste des recepteurs du cgrp
JP2011512410A (ja) 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
CA2728547A1 (fr) * 2008-06-30 2010-01-07 Merck Sharp & Dohme Corp. Formes pharmaceutiques posologiques solides telcagepant potassique
EP2348846B1 (fr) * 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine de type azépane disubstitué
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI501968B (zh) 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US20140005214A1 (en) * 2011-03-18 2014-01-02 Ian M. Bell Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
HUE047050T2 (hu) 2012-02-27 2020-04-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só
BR112014024203B1 (pt) 2012-03-29 2019-09-03 Bayer Intellectual Property Gmbh derivados de 5-aminopirimidina e sua utilização para o controle do crescimento de plantas indesejadas
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (fr) * 2015-06-29 2017-01-05 Galderma Research & Development Composés de type antagonistes des récepteurs du cgrp pour traitement par voie topique de maladies de la peau
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
EP3366286A1 (fr) 2017-02-22 2018-08-29 Johannes Keller Composés destinés au traitement de septicémie
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
EP3740477A1 (fr) 2018-01-19 2020-11-25 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur c5a
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
WO2020146527A1 (fr) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908420D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
CA3077973A1 (fr) 2020-04-06 2021-10-06 H. Lundbeck A/S Traitement du symptome le plus perturbant associe a la migraine au moyen d`anticorps anti-cgrp
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (fr) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Traitement de la migraine
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
EP4408418A1 (fr) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combinaison comprenant de l'atogépant pour le traitement de la migraine
CN116903616B (zh) * 2023-07-17 2025-08-01 江西同和药业股份有限公司 一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (fr) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides stimulant la liberation de l'hormone de croissance
WO2000018764A1 (fr) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Piperidines de benzimidazolinyle en tant que ligands de cgrp
KR20010075447A (ko) 1998-09-30 2001-08-09 우에하라 아끼라 치환 이속사졸릴 티오펜 화합물
RS52552B (sr) * 2002-06-05 2013-04-30 Bristol-Myers Squibb Company Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom
ATE466860T1 (de) * 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten

Also Published As

Publication number Publication date
IS8055A (is) 2005-09-29
NO20055375L (no) 2005-11-14
NZ543357A (en) 2008-08-29
CA2522220A1 (fr) 2004-10-28
US20100298303A1 (en) 2010-11-25
CN1802376A (zh) 2006-07-12
NO327655B1 (no) 2009-09-07
WO2004092168A1 (fr) 2004-10-28
JP2006523697A (ja) 2006-10-19
HK1090922A1 (en) 2007-01-05
US20050256098A1 (en) 2005-11-17
US6953790B2 (en) 2005-10-11
KR100769030B1 (ko) 2007-10-22
PL1638969T3 (pl) 2009-04-30
UA82877C2 (en) 2008-05-26
US20070225272A1 (en) 2007-09-27
US20080280857A1 (en) 2008-11-13
US7893052B2 (en) 2011-02-22
PE20050020A1 (es) 2005-02-18
DE602004017608D1 (de) 2008-12-18
EP2039694A1 (fr) 2009-03-25
BRPI0409601A (pt) 2006-04-18
JO2355B1 (en) 2006-12-12
CY1108714T1 (el) 2014-04-09
CL2004000788A1 (es) 2005-02-25
US7235545B2 (en) 2007-06-26
EP1638969A2 (fr) 2006-03-29
US7452903B2 (en) 2008-11-18
WO2004092166A2 (fr) 2004-10-28
PT1638969E (pt) 2009-01-16
EP2039694B1 (fr) 2014-03-26
KR20050121734A (ko) 2005-12-27
HRP20080666T3 (en) 2009-01-31
IS2759B (is) 2011-10-15
JP3967766B2 (ja) 2007-08-29
CO5640130A2 (es) 2006-05-31
CA2522220C (fr) 2009-06-23
ATE413400T1 (de) 2008-11-15
AU2004230926A1 (en) 2004-10-28
US20040229861A1 (en) 2004-11-18
RU2005135440A (ru) 2006-03-20
AR045887A1 (es) 2005-11-16
WO2004092166A3 (fr) 2005-01-20
MXPA05011166A (es) 2005-12-14
EP1638969B1 (fr) 2008-11-05
US7772224B2 (en) 2010-08-10
US7534784B2 (en) 2009-05-19
AU2004230926B2 (en) 2008-07-17
DK1638969T3 (da) 2009-01-26
SI1638969T1 (sl) 2009-02-28
ES2314417T3 (es) 2009-03-16
RU2308458C2 (ru) 2007-10-20
CN100384843C (zh) 2008-04-30
US20090192139A1 (en) 2009-07-30
TW200505903A (en) 2005-02-16
ECSP056097A (es) 2006-03-01
TWI314931B (en) 2009-09-21

Similar Documents

Publication Publication Date Title
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
DE602004026053D1 (fr)
ATE466860T1 (de) Cgrp-rezeptorantagonisten
WO2005000807A3 (fr) Antagonistes du recepteur cgrp de benzodiazepine
DE602004013563D1 (de) Rantagonisten
EP1796678A4 (fr) Carboxamide spirolactam cgrp receptor antagonists
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
EP1606264A4 (fr) Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
MA30558B1 (fr) Antagonistes de recepteurs cgrp monocycliques substitues
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
EP1794133A4 (fr) Antagonistes des recepteurs cgrp d'aryle-spirolactame
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
EP1793827A4 (fr) Antagonistes des recepteurs cgrp sous forme de spirolactame d'anilide tricyclique
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
IL182317A0 (en) Cgrp receptor antagonists
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
WO2003105771A3 (fr) 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors